scholarly journals Reactions to graphic health warnings in the United States

2014 ◽  
Vol 30 (1) ◽  
pp. 46-56 ◽  
Author(s):  
James M. Nonnemaker ◽  
Conrad J. Choiniere ◽  
Matthew C. Farrelly ◽  
Kian Kamyab ◽  
Kevin C. Davis
Health Policy ◽  
2011 ◽  
Vol 102 (1) ◽  
pp. 41-48 ◽  
Author(s):  
James F. Thrasher ◽  
Matthew C. Rousu ◽  
David Hammond ◽  
Ashley Navarro ◽  
Jay R. Corrigan

Author(s):  
Carla J Berg ◽  
Dianne C Barker ◽  
Christina Meyers ◽  
Amber Weber ◽  
Amy J Park ◽  
...  

Abstract Introduction Vape shops represent prominent, unique retailers, subject to Food and Drug Administration (FDA) regulation in the United States. Aims and Methods This study assessed compliance of US vape shop retail marketing strategies with new regulations (eg, required age verification, prohibited free samples) and pre-implementation conditions for other regulations (eg, health warning labels on all nicotine products, required disclosures of e-liquid contents). Results 95.0% of shops displayed minimum-age signage; however, mystery shoppers were asked for age verification at 35.6% upon entry and at 23.4% upon purchase. Although 85.5% of shops had some evidence of implementing FDA health warnings, 29.1% had signage indicating prohibited health claims, 16.3% offered free e-liquid samples, 27.4% had signage with cartoon imagery, and 33.3% were within two blocks of schools. All shops sold open-system devices, 64.8% sold closed-system devices, 68.2% sold their own brand of e-liquids, 42.5% sold e-liquids containing cannabidiol, 83.2% offered price promotions of some kind, and 89.9% had signage for product and price promotions. Conclusions Results indicated that most shops complied with some implementation of FDA health warnings and with free sampling bans and minimum-age signage. Other findings indicated concerns related to underage access, health claims, promotional strategies, and cannabidiol product offerings, which call for further FDA and state regulatory/enforcement efforts.


2013 ◽  
Vol 16 (5) ◽  
pp. 536-543 ◽  
Author(s):  
Sara C. Hitchman ◽  
Pete Driezen ◽  
Christine Logel ◽  
David Hammond ◽  
Geoffrey T. Fong

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 1049-1050
Author(s):  
Melissa O'Connor ◽  
Vanessa Christiuk ◽  
Megan Pedersen

Abstract The use of cannabis for therapeutic purposes is becoming more popular in many countries, including the United States and Canada. In Canada, middle-aged and older adults make up the largest proportion of medical cannabis users. Canadian legislation mandates that medical cannabis be packaged in plain-looking containers with small labels, childproof caps, and required health warnings. This is meant to standardize the way cannabis products are distributed, as well as protect children from accidental ingestion. However, there is limited research on how these regulations affect cannabis users over age 45. In the present study, residents of Winnipeg, Manitoba, Canada aged 45 and older (n=40) were surveyed regarding their experiences with medical cannabis packaging and labeling. Half of the participants (50%) felt they had a hard time opening their medical cannabis container. A majority (60%) thought having an easy-open lid would be helpful. Most participants (78%) reported experiencing difficulties reading the label on their container, and 75% thought it would be helpful to have a printout of the label in a larger font. In addition, 89% of participants who took more than one kind of medical cannabis favored a symbol on their medication bottle that would indicate the type of medical cannabis contained inside. Implications for policy makers and future research are discussed.


2016 ◽  
Vol 4 ◽  
pp. 205031211665305 ◽  
Author(s):  
Eduardo Carracedo-Martínez ◽  
Agustin Pia-Morandeira

Background: Throughout 2007 and January 2008, several glitazones health warnings were published on rosiglitazone myocardial infarction risk. The impact of such warnings on glitazones prevalence of utilization has been extensively studied in the United States but only in one European country (England), which has showed different pattern from US studies. The aim of this study is to evaluate the impact of such safety warnings on glitazones utilization in an area of another European country. Methods: We calculated the number of defined daily doses per thousand inhabitants per day of glitazones each month during the period from 2006 to 2008 in a health area of Spain. We analyzed the data graphically and through a segmented regression analysis. Results: Rosiglitazone defined daily doses per thousand inhabitants per day were growing before the safety warnings, after the warnings a change in trend occurred and rosiglitazone utilization showed a downturn slope. Pioglitazone defined daily doses per thousand inhabitants per day were stable before the safety warnings, and a linear growth was observed after the safety warnings. Throughout the study period, rosiglitazone defined daily doses per thousand inhabitants per day were higher than pioglitazone defined daily doses per thousand inhabitants per day until near the end of 2008. Conclusion: Despite the fact that cardiovascular warnings affected rosiglitazone and not pioglitazone, rosiglitazone was more utilized than pioglitazone until near the end of 2008 which is a pattern similar to the one found in another European studies in England, but very different from studies in the United States, where rosiglitazone was less utilized than pioglitazone from the first month after rosiglitazone cardiovascular safety warnings.


Sign in / Sign up

Export Citation Format

Share Document